1. Главная
  2. Ресурсы
  3. Библиотечный поиск
EmicizumabProphylaxis inHemophilia A withInhibitors Johannes OldenburgJohnny MahlanguBenjamin Kim2017 год

Emicizumab Prophylaxis in Hemophilia A with Inhibitors
статья из журнала

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: Emicizumab (ACE910) bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in persons with hemophilia A. This phase 3, multicenter trial assessed once-weekly subcutaneous emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors.
Год издания: 2017
Авторы: Johannes Oldenburg, Johnny Mahlangu, Benjamin Kim, Christophe Schmitt, Michael U. Callaghan, Guy Young, Elena Santagostino, Rebecca Kruse‐Jarres, Claude Négrier, Craig M. Kessler, Nancy Valente, Elina Asikanius, Gallia G. Levy, Jerzy Windyga, Midori Shima
Издательство: Massachusetts Medical Society
Источник: New England Journal of Medicine
Ключевые слова: Hemophilia Treatment and Research, Blood Coagulation and Thrombosis Mechanisms, Platelet Disorders and Treatments
Другие ссылки: New England Journal of Medicine (PDF)
New England Journal of Medicine (HTML)
PubMed (HTML)